Vorgehen und antithrombotische Therapie bei Elektrokardioversion

Christine S. Zürn; Axel Bauer

doi:10.1055/s-0032-1310240

Kardiologie up2date, Table of Contents

Kardiologie up2date 2012; 08(03): 221-232
DOI: 10.1055/s-0032-1310240

Thrombozyten und Gerinnungssystem bei kardiovaskulären Erkrankungen

Vorgehen und antithrombotische Therapie bei Elektrokardioversion

Christine S. Zürn

,

Axel Bauer

Abstract

All articles of this category

Abstract

Electrical cardioversion is an effective method for restoration of sinus rhythm in patients with atrial fibrillation. Both success and safety of the procedure depend on a precise selection of patients and on an adequate preparation. Patients who are hemodynamically compromised have to undergo electrical cardioversion immediately. Other patients should undergo electrical cardioversion if they have the chance of a sustained maintenance of sinus rhythm. Before electrical cardioversion, heparin has to be administered in all patients. Patients with atrial fibrillation > 48 hours need to undergo oral anticoagulation for at least three weeks or to undergo transesophageal echocardiography for exclusion of a left atrial thrombus. After electrical cardioversion oral anticoagulation should be administered for at least four weeks or lifelong depending on the patient’s risk factors. Antiarrhythmic drugs can enhance the effect of electrical cardioversion.

Full Text

References

Literatur
1 Lown B, Amarasingham R, Neuman J. New method for terminating cardiac arrhythmias. Use of synchronized capacitor discharge. JAMA 1962; 182: 548-555
2 Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833
3 Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840
4 DeSilva RA, Graboys TB, Podrid PJ et al. Cardioversion and defibrillation. Am Heart J 1980; 100: 881-895
5 Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967; 29: 469-489
6 Gurevitz OT, Ammash NM, Malouf JF et al. Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter. Am Heart J 2005; 149: 316-321
7 Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429
8 Gulamhusein S, Ko P, Carruthers SG et al. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation 1982; 65: 348-354
9 Singh BN, Singh SN, Reda DJ et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352: 1861-1872
10 Kirchhof P, Eckardt L, Loh P et al. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 2002; 360: 1275-1279
11 Fetsch T, Bauer P, Engberding R et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004; 25: 1385-1394
12 Gentile F, Elhendy A, Khandheria BK et al. Safety of electrical cardioversion in patients with atrial fibrillation. Mayo Clin Proc 2002; 77: 897-904
13 Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 546S-592S
14 Klein AL, Grimm RA, Murray RD et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344: 1411-1420
15 Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272
16 Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304
17 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867
18 Weigner MJ, Thomas LR, Patel U et al. Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. Am J Med 2001; 110: 694-702
19 Gallagher MM, Hennessy BJ, Edvardsson N et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol 2002; 40: 926-933
20 Seidl K, Rameken M, Drogemuller A et al. Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen Observational Cardioversion Study. J Am Coll Cardiol 2002; 39: 1436-1442
21 Mittal S, Ayati S, Stein KM et al. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation 2000; 101: 1282-1287
22 Skulec R, Belohlavek J, Kovarnik T et al. Serum cardiac markers response to biphasic and monophasic electrical cardioversion for supraventricular tachyarrhythmia – a randomised study. Resuscitation 2006; 70: 423-431
23 Dahl CF, Ewy GA, Warner ED et al. Myocardial necrosis from direct current countershock. Effect of paddle electrode size and time interval between discharges. Circulation 1974; 50: 956-961
24 Kirchhof P, Monnig G, Wasmer K et al. A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). Eur Heart J 2005; 26: 1292-1297
25 Oral H, Souza JJ, Michaud GF et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999; 340: 1849-1854
26 Manios EG, Mavrakis HE, Kanoupakis EM et al. Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study. Cardiovasc Drugs Ther 2003; 17: 31-39
27 Bianconi L, Mennuni M, Lukic V et al. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol 1996; 28: 700-706
28 Sung RJ. Facilitating electrical cardioversion of persistant atrial fibrillation by antiarrhythmic drugs: update on clinical trial results. Card Electrophysiol Rev 2003; 7: 300-303
29 Madrid AH, Bueno MG, Rebollo JM et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331-336
30 Ueng KC, Tsai TP, Yu WC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090-2098
31 Nagarakanti R, Ezekowitz MD, Oldgren J et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-136